MedTrace Logo

Prognostic Factors for Treatment Responses in Patients With Active Lupus Nephritis at Sohag University Hospital

NCT04756492 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2021-02-16

No results posted yet for this study

Summary

Systemic lupus erythematosus (SLE) is an autoimmune disease which may give rise to multiple organ involvement because of immune complex deposits. Lupus nephritis (LN) is one of the severe manifestations of systemic lupus erythematous (SLE) and a common cause for end-stage renal disease, significantly affecting the survival of SLE patients Immunosuppressive treatment is the major therapy for active LN. Generally, at least six months are needed to assess treatment responses Failure to respond to immunosuppressive therapy can lead to a worsening of renal function

Conditions

  • We Aim to Examine the Predictors of Sustained Complete Renal Remission in Patients With Lupus Nephritis at Sohag University Hospital

Interventions

DRUG

sandimmun

follow up for treatment response

Sponsors & Collaborators

  • Sohag University

    lead OTHER

Eligibility

Min Age
14 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-15
Primary Completion
2023-02-15
Completion
2023-02-15

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04756492 on ClinicalTrials.gov